Search

everythinglearnresearchcommunity

for

Search:↓

Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.

Combining delgocitinib ointment with excimer laser can effectively treat severe alopecia areata.

Naringin may help treat atopic dermatitis by reducing inflammation and improving the skin barrier.

Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.

Most children with alopecia areata improved with treatment, but those with more hair loss had worse outcomes.

Baricitinib helps long-term hair regrowth in severe alopecia areata patients.

Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.

Specific immune cells and pathways contribute to hair follicle inflammation and hair loss, suggesting potential treatments for lichen planopilaris.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

Tofacitinib helped most teenagers in the study regrow hair with mild side effects.

SCD-153 shows promise as an effective topical treatment for alopecia areata.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

The immune processes causing VKH and vitiligo are similar in dogs and humans.

Biologics and JAK inhibitors may improve treatment for scarring alopecias.

JAK inhibitors help hair regrowth but not fully effective for androgenetic alopecia.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

Vitiligo is a systemic disease with psychological effects, and new treatments focus on personalized care.

Blocking JAK1 or JAK3 helps reverse hair loss in a mouse model of alopecia areata.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.

New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.

A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.

A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.

JAK inhibitors helped treat hair loss in two people with Down syndrome.

Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.

Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.

The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.

A COVID-19 patient with severe hair loss did not improve with hair loss medication after stopping and restarting it due to the infection.